Long-term outcomes of (131)Iodine mIBG therapy in metastatic gastrointestinal pancreatic neuroendocrine tumours: single administration predicts non-responders.
Nicola MulhollandRiddhika ChakravarttyLindsey DevlinEleni KalogianniBen CorcoranGillian VivianPublished in: European journal of nuclear medicine and molecular imaging (2015)
Biochemical, radiological (RECIST 1.1) and symptomatic assessment of disease status at 3 to 6 months after first I131-mIBG therapy stratifies patients with a poor prognosis. This can be used to identify patients who may benefit from alternative strategies of treatment.